GLP-1 receptor agonists × kidney outcomes

TrialDiabetes care2016

Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial.

Thomas Idorn et al.PubMed ↗Publisher ↗

What the trial testedas reported · 2016

Not counted

Probably raised kidney outcomes

+49.0percentage points+6.00 to +109

As reported

difference 49 %, 95% CI 6.00–109

One number in the abstract

the abstract, start to end

at the final visit was increased by 49% (95% CI 6-109, P = 0.02) in

← favours treatmentfavours comparator →
could be chance
Kidney outcomes
496.00–109
GLP-1 receptor agonistsKidney outcomes
1 / 3

49 papers cite it

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 26283739